SpectronRx

Based in the US, SpectronRx is a specialized provider of radiopharmaceuticals, focusing on the comprehensive management of drug lifecycles, from concept through to FDA approval, catering to the pharmaceutical and biotechnology sectors. SpectronRx was founded in 2004 in South Bend, US, and specializes in the development of radiopharmaceuticals. The company has successfully completed a funding round led by OrbiMed Advisors in April 2026, raising USD 85 mn to enhance their production capabilities. No mention has been made of any subsidiaries, parent companies, or significant pivots in their business strategy since inception.

The founder's history, including previous ventures, is not documented. SpectronRx specializes in the development and regulatory consulting for radiopharmaceuticals, focusing on end-to-end management of drug lifecycles from conception to full FDA approval. The company provides advanced solutions for the labeling of monoclonal antibodies (mAb), nanobodies, and peptides, using a variety of isotopes for therapeutic and diagnostic applications. Their services are tailored to meet the complex needs of clients in the pharmaceutical and biotechnology sectors, ensuring safe and effective drug delivery throughout the drug development process.

SpectronRx serves a global clientele, including pharmaceutical manufacturers and research institutions across North America, Europe, and Asia, leveraging their expertise in logistics and regulatory strategies to enable international compliance and transactions. SpectronRx operates on a business-to-business (B2B) model, generating revenue through partnerships with pharmaceutical companies and research organizations. Their income is derived from various service agreements, which may cover shared or full-service GMP manufacturing, regulatory consulting, and logistics support. These agreements are designed to navigate the complexities of drug development, including FDA filings and isotope procurement.

While specific pricing details remain undisclosed, the firm's offerings are structured to meet the pharmaceutical industry's demands, ensuring consistent revenue through contractual agreements with both domestic and international clients. In April 2026, SpectronRx raised USD 85 mn in venture funding from OrbiMed Advisors to expand their medical isotope production and radiopharmaceutical manufacturing capabilities. This funding will be allocated towards new production infrastructure, equipment, and facilities to meet customer demand. The company does not currently have publicly available information on upcoming product launches or specific geographic market expansions.